Press coverage about Aquinox Pharmaceuticals (NASDAQ:AQXP) has been trending somewhat positive recently, Accern Sentiment Analysis reports. The research firm ranks the sentiment of media coverage by reviewing more than twenty million news and blog sources in real time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Aquinox Pharmaceuticals earned a coverage optimism score of 0.17 on Accern’s scale. Accern also gave headlines about the company an impact score of 46.4891537022263 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the near term.

Aquinox Pharmaceuticals (NASDAQ:AQXP) traded down 0.14% on Friday, hitting $14.19. The stock had a trading volume of 31,305 shares. The firm’s market cap is $332.95 million. Aquinox Pharmaceuticals has a 1-year low of $9.83 and a 1-year high of $19.97. The firm’s 50-day moving average price is $14.27 and its 200-day moving average price is $14.45.

Aquinox Pharmaceuticals (NASDAQ:AQXP) last released its earnings results on Tuesday, August 8th. The company reported ($0.59) EPS for the quarter, meeting the Thomson Reuters’ consensus estimate of ($0.59). On average, equities research analysts predict that Aquinox Pharmaceuticals will post ($2.15) earnings per share for the current year.

A number of brokerages recently commented on AQXP. BidaskClub upgraded Aquinox Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Friday, August 4th. Canaccord Genuity set a $22.00 price objective on Aquinox Pharmaceuticals and gave the stock a “buy” rating in a research note on Tuesday, August 8th. Zacks Investment Research upgraded Aquinox Pharmaceuticals from a “hold” rating to a “buy” rating and set a $15.00 price objective for the company in a research note on Thursday, August 10th. Finally, ValuEngine downgraded Aquinox Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Friday, September 15th. One research analyst has rated the stock with a sell rating, two have issued a hold rating and four have given a buy rating to the stock. The company currently has an average rating of “Hold” and a consensus price target of $22.25.

COPYRIGHT VIOLATION WARNING: “Aquinox Pharmaceuticals (AQXP) Getting Somewhat Favorable Press Coverage, Analysis Finds” was originally posted by Watch List News and is the sole property of of Watch List News. If you are accessing this story on another publication, it was illegally copied and republished in violation of U.S. & international trademark and copyright legislation. The correct version of this story can be viewed at

Aquinox Pharmaceuticals Company Profile

Aquinox Pharmaceuticals, Inc is a clinical-stage pharmaceutical company discovering and developing targeted therapeutics in disease areas of inflammation and immuno-oncology. The Company’s primary focus is anti-inflammatory product candidates targeting the Src Homology 2 (SH2)-containing inositol-5-phosphatase 1 (SHIP1) enzyme, which is a regulator of a cellular signaling pathway in immune cells, known as the phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3K) pathway.

Insider Buying and Selling by Quarter for Aquinox Pharmaceuticals (NASDAQ:AQXP)

Receive News & Ratings for Aquinox Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aquinox Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.